Last updated: June 13, 2026
Suppliers of Potassium Chloride 0.037% in Dextrose 5% (Plastic Container) IV Solution
Executive summary: No complete, reliable supplier roster can be produced from the available information. A defensible list requires drug-specific sourcing tied to the exact product identity (strength, container type, NDA/labeler, and FDA product code) and to FDA listings (Orange Book/Drug Product Database) or current contracted supply records. Without those identifiers, any “supplier” list would risk mixing different potassium chloride in dextrose presentations, different container materials, or different labeled concentrations.
Which companies supply potassium chloride 0.037% in dextrose 5% in plastic containers?
Answer: Not determinable from the provided input.
What product identifiers are needed to match suppliers to the exact listing?
- FDA drug product listing: labeler (firm), NDA (or ANDA if applicable), dosage form, strength, and container.
- Package configuration: “plastic container” can map to multiple systems (commonly VIAFLEX or similar PVC-free/non-PVC technologies, but the exact container standard must match the FDA listing).
- Label description: exact wording of “Potassium Chloride 0.037% in Dextrose 5%” (some products exist as compounded admixtures under NDCs, others as manufacturer-filled premixes).
How does FDA listing (NDC/labeler) determine true suppliers for this IV admixture?
Answer: Not determinable from the provided input.
Orange Book vs. FDA drug product listing for supplier discovery
- Orange Book: primarily for approved active ingredient patents (useful for IP and exclusivity, not a definitive supplier list by itself).
- FDA Drug Product Database: the practical source for matching a specific NDC and labeler to market-facing suppliers.
What are the major supply channels for this IV potassium chloride in dextrose product?
Answer: Not determinable from the provided input.
Common channels used for IV small-volume and admixture products
- Manufacturer-produced premixes (fixed formulation).
- Contract manufacturing and relabeling.
- In-hospital pharmacy compounding (USP <797> compliant preparation).
- Outsourced compounding pharmacies (for shortages or custom admixture needs).
Is this product manufactured as a premix or compounded (and how does that change the supplier map)?
Answer: Not determinable from the provided input.
Why premix vs. compounded matters for supplier counts
- Premix: suppliers map to FDA-listed finished dosage units with specific NDCs.
- Compounded: supply maps to compounding pharmacies and 503B outsourcing facilities, often with different NDC or no direct NDC comparability.
What generic entry risks exist for potassium chloride in dextrose 5% IV products?
Answer: Not determinable from the provided input.
What drives generic risk for IV potassium chloride admixtures
- Whether the product is an approved NDA with an ANDA pathway.
- Whether it is repackaged vs. a fixed premix.
- Patent estate scope tied to composition and/or manufacturing process.
When does exclusivity or patent protection for this product expire?
Answer: Not determinable from the provided input.
Key drivers
- NDA approval date and any pediatric exclusivity.
- Listed patents in the Orange Book tied to the specific NDC.
- Method-of-use or formulation patents that can block certain manufacturing approaches.
Which contract manufacturers or relabelers build this product in plastic containers?
Answer: Not determinable from the provided input.
Why contract manufacturer attribution is hard without NDC/NDA
- FDA lists “labeler,” not always the actual fill site.
- Reverse attribution usually requires NDA supplement histories, inspection databases, or label manufacturing statement review.
What formulations are protected, and do any container-related patents apply?
Answer: Not determinable from the provided input.
Typical patent categories for IV admixtures
- Composition claims (fixed concentration of potassium chloride in dextrose).
- Manufacturing/sterility and mixing process claims.
- Container closure system claims (less common for generic lines, but possible for specialized systems).
Key Takeaways
- A supplier roster cannot be produced from the product description alone.
- Any accurate supplier mapping requires the exact FDA-listed product identity (NDC/labeler and, if available, NDA) tied to “potassium chloride 0.037% in dextrose 5%” and the specific “plastic container” configuration.
FAQs
- How do I find the exact NDC for “potassium chloride 0.037% in dextrose 5% in plastic container”?
- Do wholesalers list suppliers under the NDC labeler, or do they reflect actual manufacturers?
- Is potassium chloride in dextrose 5% available as a premix in multiple plastic container systems?
- When shortages occur, do 503B outsourcing facilities supply this type of IV admixture?
- What is the fastest way to validate a supplier using FDA drug product listings?
References
No sources were cited because no drug-specific FDA or Orange Book identifiers were provided.
